Skip to Content

Disclaimer

Disclaimer
MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

 
International Parkinson and Movement Disorder Society

 

Mild Cognitive Impairment in Parkinson Disease (PD-MCI) Study Group

Main Content

Join now »

Have questions? Contact the group’s MDS Staff Liaison, Finoula Harrington, at fharrington@movementdisorders.org

Goals

1. Validation of the MDS PD-MCI criteria

  • comparison of the two levels of criteria (abbreviated assessment {I} versus comprehensive assessment {II}) in their ability to detect PD-MCI and predict conversion to dementia
  • applicability of the criteria

2. Generating epidemiologic data by defining the prevalence of PD-MCI

3. Determine relationship PD-MCI, mood, and Quality of Life by analyzing mood and Quality of Life in no-PD-MCI, PD-MCI and PDD groups.

View the group's: 

 

Current Projects

Validation of the MDS diagnostic criteria for MCI in PD (PD-MCI)

The recently proposed MDS diagnostic criteria for MCI in PD (PD-MCI) need to be validated. This Study Group will validate these criteria by:

  1. combining and analyzing comprehensive neuropsychological cross-sectional data-bases and longitudinal data-bases (follow up at least one year) {≥ 3,500 PD patients and ≥ 1,400 controls};
  2. applying the MDS PD-MCI criteria to validate Level I in 3,000 patients and Level II in 1,000 patients;
  3. investigating the predictive value of the PD-MCI criteria;
  4. revise the MDS PD-MCI criteria if necessary

23 international sites have PD cohorts that will be combined. These cohorts include ≥ 3,500 PD patients and ≥ 1,400 controls. Two PhD students started in October 2013 and we are currently finalizing the validation project. An overview of the research plans is published in the Journal of Parkinson’s Disease and a validation papers have been published.

Papers on level I and Level II PD-MCI criteria have been published. Other manuscript is being prepared now.

Leadership

Jennifer G. Goldman
Chair 
Jennifer G. Goldman

Gert J. Geurtsen
Vice Chair
Gert J. Geurtsen


Vice Chair
Alexander I. Tröster

Steering Committee

Irene Litvan PhD
Ben A. Schmand PhD
Alexander I. Trőster PhD
Jennifer G. Goldman PhD
David J. Burn PhD

Resource Type

Please wait while we gather your results.

Project Archive

Open AllClose All
  Activities
  • Study Group meetings at MDS congress (Sydney; Stockholm, San Diego, Berlin Vancouver, HongKong and Nice);
  • Manuscript published in Journal of Parkinson’s Disease:Geurtsen GJ, Hoogland J, Goldman JG, Schmand BA, Trőster AI, Burn DJ, Litvan  I. Parkinson's Disease Mild Cognitive Impairment: Application and Validation of the Criteria. J Parkinson’s Dis. 2014 (4): 131-137;
  • Presented preliminary results at NMPD in Nice and British-Dutch Neuropsychological Association, at MDS meeting in San Diego and NMPD meeting in Ljubljana, at MDS meeting in Berlin and Vancouver;
  • Paper on level II PD-MCI criteria published: Hoogland J, Boel JA, Bie RMA de, Geskus RB, Schmand BA, Dalrymple-Alford JC, Marras C, Adler CH, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”. Mild cognitive impairment as a risk factor for Parkinson’s disease dementia. Movement Disorders 2017; 32(7):1056-1065;
  • Performed additional project on PD-MCI PDD and DNA/genetic markers in cooperation with Matt Farrer; Paper published: Guella I, Evans DM, Szu-Tu C, Nosova E, Bortnick SF, Goldman JG, Dalrymple-Alford J, Geurtsen GJ, Litvan I, Ross OA, Middleton LT, Parkkinen L,  Farrer MJ. α-synuclein genetic variability: a biomarker for dementia in Parkinson’s disease. Annals of Neurology 2016; 79(6):991-999;Performed an additional project on in cooperation with Daniel Weintraub: Parkinson Neuropsychological Battery: Which tests best differentiate PD from controls; Paper published: Hoogland J, Wanrooij LL van, Boel JA, Goldman JG, Stebbins GT, Dalrymple-Alford JC, Marras C, Adler CH, Junque C, Pedersen KF, Mollenhauer B, Zabetian CP, Eslinger PJ, Lewis SJG, Wu RM, Klein M, Rodriguez-Oroz MC, Cammisuli DM, Barone P, Biundo R, Bie RMA de, Schmand BA, Tröster AI, Burn DJ, Litvan I, Filoteo JV, Geurtsen GJ #, and Daniel Weintraub MD #, on behalf of the IPMDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”. Detecting mild cognitive deficits in Parkinson disease: comparison of neuropsychological tests. Movement Disorders. 2018; 33(11): 1750-1759.
  • Prepared an additional project on PD-MCI dementia risk score in cooperation with John Dalrymple-Alford, Tim Anderson and Matt Farrer. Looking for funding;
  • Paper validation of level I PD-MCI published; Hoogland J, Boel JA, Bie RMA de, Schmand BA, Geskus RB, Dalrymple-Alford JC, Marras C, Adler CH, Weintraub D, Junque C, Pedersen KF, Mollenhauer B, Goldman JG, Tröster AI, Burn DJ, Litvan I, Geurtsen GJ on behalf of the MDS Study Group “Validation of Mild Cognitive Impairment in Parkinson Disease”. Risk of Parkinson’s disease dementia related to level I MDS PD-MCI. Movement Disorders 2019; 34(3): 430-435.
  • Currently preparing analysis of predictive value of screeners for dementia compared to level I and II PD-MCI.
  Grants
  • Michael J. Fox Foundation;
  • Parkinson Vereniging (Dutch Parkinson’s Disease Association);
  • Additional grant concerning Michael J. Fox Foundation (Parkinson Neuropsychological Battery);
  • Additional grant concerning Michael J. Fox Foundation (α-synuclein genetic variability);
  • Additional grant concerning Michael J. Fox Foundation (Comparison screeners versus Level I and Level II).
  Spin-off Projects
  • Finished additional project on PD-MCI/PDD and DNA/genetic markers in cooperation with Matt Farrer; paper  Guella et al. α-synuclein genetic variability: a biomarker for dementia in Parkinson’s disease. Annals of Neurology 2016; 79(6):991-999;
  • Finished additional project on in cooperation with Daniel Weintraub: Parkinson Neuropsychological Battery: Which tests best differentiate PD from controls; Paper published.
  • In preparation project on enhanced dementia risk score based on neuropsychological tests and genetics;

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including mds.movementdisorders.org and mds.execinc.com. This cookie policy only covers the primary movementdisorders.org and mdscongress.org domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice

Cookie Settings

  • Your Privacy

  • Strictly Necessary

  • Performance

  • Targeting/Advertising

Your Privacy

When you visit a website, it may collect information about your browser, your preferences, or your device to make the website work as you expect it to. This information is collected in the form of cookies. The information collected does not identify you directly, but it can give you a more personalized website experience. The following describes the different types of cookies we are using and gives you the option to not allow some types of cookies. Click on the category headings to learn more and change your default cookie settings. Please note that blocking some types of cookies may impact your website experience.

Strictly Necessary

Always Enabled

These cookies are essential in order to enable you to move around the website and use its features. Without these cookies, website services, such as remembering your shopping cart items, cannot be provided. We are unable to turn these cookies off in the system. While you may be able to set your browser to block or alert you about these cookies, some parts of the website will not function without them.

Modules:

Performance

These cookies collect anonymous information on how people use the website: website visits, traffic sources, click patterns and similar metrics. They help us understand what pages are the most popular. All of the information collected is aggregated and therefore anonymous. If you do not allow these cookies, we will not know when you have visited our website.

Modules:

Targeting/Advertising

These cookies collection information about your browsing habits in order to make advertising more relevant to you and your interests. They are set up through our advertising partners, who compile your interests and target you with relevant ads on other websites or platforms. If you do not allow these cookies, you will not experience our targeted advertising on other places throughout the web.

Modules: